On the morning of April 29th, GPHL held the 2020 Q1 economic work conference at its subsidiary Baiyunshan Pharmaceutical’s General Factory. The group reviewed their work in Q1, analyzed the the ‘post-epidemic period’ and made arrangements for the next stages of production and operation.

Li pointed out that the results should be considered in a rational way. As a result of the pandemic, GPHL achieved sales revenue of 35.03 billion RMB in Q1, a year-on year increase of 0.12%, and a total profit of 1.696 billion RMB, a year-on-year decrease of 12.43%. This is against a backdrop of overall economic decline across the country. “In terms of data, GPHL has a better performance than average. We should therefore have full confidence in the year’s development,” Li said.

Editors: Olivia Yang, Simon Haywood